NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis $5.30 +0.65 (+13.98%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Eledon Pharmaceuticals Stock (NASDAQ:ELDN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eledon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.66▼$5.5450-Day Range$2.44▼$5.3052-Week Range$1.07▼$5.54Volume1.14 million shsAverage Volume774,330 shsMarket Capitalization$210.20 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company OverviewEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Read More… He made 1,303,329 in 12 months after Biden won… (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Eledon Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreELDN MarketRank™: Eledon Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 459th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEledon Pharmaceuticals has received no research coverage in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.52) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 17.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.36% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 20.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.36% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 20.49%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment0.59 News SentimentEledon Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest14 people have searched for ELDN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.70% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Stock News HeadlinesPromising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling InvestmentOctober 30 at 2:55 PM | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)October 30 at 2:55 PM | markets.businessinsider.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Buy Rating Justified for Eledon Pharmaceuticals Amid Promising Clinical Developments and Financial StabilityOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offeringOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial DataOctober 29, 2024 | marketwatch.comEledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartOctober 29, 2024 | seekingalpha.comEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOctober 29, 2024 | globenewswire.comSee More Headlines ELDN Stock Analysis - Frequently Asked Questions How have ELDN shares performed this year? Eledon Pharmaceuticals' stock was trading at $1.80 at the start of the year. Since then, ELDN shares have increased by 194.4% and is now trading at $5.30. View the best growth stocks for 2024 here. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its earnings results on Monday, August, 19th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. Who are Eledon Pharmaceuticals' major shareholders? Top institutional shareholders of Eledon Pharmaceuticals include Clarity Capital Partners LLC (0.03%). View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eledon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/19/2024Today11/02/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELDN CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+201.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-233.17% Return on Assets-45.44% Debt Debt-to-Equity RatioN/A Current Ratio14.48 Quick Ratio14.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book17.67Miscellaneous Outstanding Shares39,660,000Free Float35,016,000Market Cap$210.20 million OptionableOptionable Beta0.76 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:ELDN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.